高级检索
中华实验眼科杂志
期刊首页
过刊列表
高级检索
稿件发表
• 综述 •
ENGLISH ABSTRACT
钠－葡萄糖共转运蛋白及其抑制剂对DR的影响研究进展
陈姝历
邹海东 [综述]
作者及单位信息
·
DOI： 10.3760/cma.j.cn115989-20210325-00206
Research progress on the effects of sodium-glucose cotransporters and their inhibitors on DR
Chen Shuli
Zou Haidong
Authors Info & Affiliations
Chen Shuli
Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Eye Disease Prevention and Treatment Center/Shanghai Eye Hospital, Shanghai Engineering Research Center of Precise Diagnosis and Treatment of Eye Diseases, Shanghai 200080, China
Zou Haidong
Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Eye Disease Prevention and Treatment Center/Shanghai Eye Hospital, Shanghai Engineering Research Center of Precise Diagnosis and Treatment of Eye Diseases, Shanghai 200080, China
·
DOI： 10.3760/cma.j.cn115989-20210325-00206
0
0
0
0
0
0
PDF下载
APP内阅读
摘要

糖尿病视网膜病变(DR)是一类常见的糖尿病微血管并发症，其发病机制目前尚未完全明确。钠－葡萄糖共转运蛋白(SGLT)是一类调控葡萄糖运输的跨膜蛋白家族，既往研究在视网膜内发现其家族成员SGLT1和SGLT2的表达，提示SGLT对DR发病具有潜在影响。SGLT2介导视网膜周细胞的异常钠依赖性葡萄糖摄取，可能参与了DR早期的微血管病变过程，而SGLT抑制剂可减少高血糖引起的视网膜细胞形态及功能损伤，可能对DR有治疗作用。近期研究发现，编码SGLT2的 SLC5A2基因多态性与DR发生风险存在相关性。SGLT2抑制剂目前在临床上用于治疗2型糖尿病，其有助于预防继发的心血管和肾脏相关病变，但关于其在DR疗效方面的研究较少。现有研究结果提示，SGLT2抑制剂对DR具有治疗作用，可能是通过控制DR相关的危险因素、保护视网膜微血管系统、减轻神经相关视网膜病变等机制实现的。本文就SGLT对DR发病的影响、SGLT2抑制剂在预防和治疗DR方面的最新研究进展以及可能的保护机制进行综述。

钠－葡萄糖共转运蛋白;糖尿病视网膜病变;钠－葡萄糖共转运蛋白2抑制剂
ABSTRACT

Diabetic retinopathy (DR) is a common type of diabetic microvascular complications.Its pathogenesis has not been clarified yet.Sodium-glucose cotransporter (SGLT) is a family of transmembrane proteins that regulate glucose transport.Previous studies have found the expression of its family members SGLT1 and SGLT2 in the retina, suggesting SGLT have a potential impact on the occurrence of DR.The abnormal sodium-dependent glucose uptake of retinal pericytes mediated by SGLT2 may be involved in the early microangiopathy process of DR, while SGLT inhibitors can weaken the morphological and functional impairment of retinal cells caused by hyperglycemia and therefore potentially manage DR.A recent study has found that the polymorphism of the SLC5A2 gene encoding SGLT2 is associated with the risk of DR occurrence.SGLT2 inhibitors are currently used in the treatment of type 2 diabetes mellitus, and have been found to help prevent secondary cardiovascular and renal diseases.However, there are few studies on the efficacy of SGLT2 inhibitors in DR.Current research results suggest that SGLT2 inhibitors have a protective effect on DR, which may be achieved through mechanisms such as controlling DR-related risk factors, protecting the retinal microvascular system and alleviating nerve-related retinopathy.This review summarizes the effects of SGLT on the pathogenesis of DR, the latest research progress of SGLT2 inhibitors studies on prevention and treatment of DR as well as possible protective mechanisms.

Sodium-glucose transport proteins;Diabetic retinopathy;Sodium-glucose transporter 2 inhibitors
Zou Haidong, Email: nc.defudabe.utjsgnodiahuoz
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文

陈姝历,邹海东. 钠－葡萄糖共转运蛋白及其抑制剂对DR的影响研究进展[J]. 中华实验眼科杂志,2024,42(08)：744-749.

DOI:10.3760/cma.j.cn115989-20210325-00206

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

糖尿病视网膜病变(diabetic retinopathy，DR)是糖尿病常见的微血管并发症之一，是糖尿病患者视力丧失的常见原因，也是工作年龄段人群致盲的主要原因 [ 1 ]。据估计，全球DR患者人数将从2011年的1.266亿增加到2030年的1.91亿 [ 2 ]。患者体内血糖水平与DR发生和发展之间的相关性已得到证实 [ 3 ]。至今为止，葡萄糖进入视网膜后继发视网膜病变的确切机制仍不完全清楚。钠－葡萄糖共转运蛋白(sodium-glucose cotransporter，SGLT)是转运葡萄糖的关键分子之一，其家族成员广泛分布于全身各脏器。最近的研究发现，SGLT1、SGLT2在视网膜组织上也有表达，参与了视网膜细胞的葡萄糖代谢，可能与DR的发生和发展相关 [ 4 , 5 ]。本文就SGLT1、SGLT2对DR发病的影响，以及SGLT2抑制剂预防及治疗DR的潜在临床价值进行综述，以期为DR的治疗提供新的思路。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
韩珺琳，韩梅．糖尿病视网膜病变相关基因单核苷酸多态性[J]. 中华实验眼科杂志， 2019，37(5)∶390－395. DOI： 10.3760/cma.j.issn.2095-0160.2019.05.014 .
返回引文位置Google Scholar
百度学术
万方数据
Han JL ， Han M ．Research progress on single nucleotide polymorphisms of genes associated with diabetic retinopathy[J]. Chin J Exp Ophthalmol， 2019，37(5)∶390－395. DOI： 10.3760/cma.j.issn.2095-0160.2019.05.014 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[2]
Zheng Y ， He M ， Congdon N ．The worldwide epidemic of diabetic retinopathy[J]. Indian J Ophthalmol， 2012，60(5)∶428－431. DOI： 10.4103/0301-4738.100542 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Yau JW ， Rogers SL ， Kawasaki R ，et al. Global prevalence and major risk factors of diabetic retinopathy[J]. Diabetes Care， 2012，35(3)∶556－564. DOI： 10.2337/dc11-1909 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Herat LY ， Matthews VB ， Rakoczy PE ，et al. Focusing on sodium glucose cotransporter-2 and the sympathetic nervous system：potential impact in diabetic retinopathy[J/OL]. Int J Endocrinol， 2018，2018∶9254126[2023－12－12]. https://pubmed.ncbi.nlm.nih.gov/30123269/. DOI： 10.1155/2018/9254126 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Wakisaka M ， Nagao T ．Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy[J]. Glycobiology， 2017，27(8)∶691－695. DOI： 10.1093/glycob/cwx047 .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Wright EM ， Loo DD ， Hirayama BA . Biology of human sodium glucose transporters[J]. Physiol Rev， 2011，91(2)∶733－794. DOI： 10.1152/physrev.00055.2009 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Chen J ， Williams S ， Ho S ，et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members[J]. Diabetes Ther， 2010，1(2)∶57－92. DOI： 10.1007/s13300-010-0006-4 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Wright EM ， Hirayama BA ， Loo DF . Active sugar transport in health and disease[J]. J Intern Med， 2007，261(1)∶32－43. DOI： 10.1111/j.1365-2796.2006.01746.x .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Sha W ， Wen S ， Chen L ，et al. The role of SGLT2 inhibitor on the treatment of diabetic retinopathy[J/OL]. J Diabetes Res， 2020，2020∶8867875[2023－12－10]. https://pubmed.ncbi.nlm.nih.gov/33274239/. DOI： 10.1155/2020/8867875 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Lu L ， Seidel CP ， Iwase T ，et al. Suppression of GLUT1；a new strategy to prevent diabetic complications[J]. J Cell Physiol， 2013，228(2)∶251－257. DOI： 10.1002/jcp.24133 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
You ZP ， Zhang YL ， Shi K ，et al. Suppression of diabetic retinopathy with GLUT1 siRNA[J/OL]. Sci Rep， 2017，7(1)∶7437[2023－12－10]. https://pubmed.ncbi.nlm.nih.gov/28785055/. DOI： 10.1038/s41598-017-07942-x .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Rizzolo LJ . Glucose transporters in retinal pigment epithelium development[M]// Tombran-Tink J ， Barnstable CJ . Ophthalmology research：ocular transporters in ophthalmic diseases and drug delivery. Totowa：Humana Press， 2008∶185－199. DOI： 10.1007/978-1-59745-375-2_10 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Gnana-Prakasam JP ， Veeranan-Karmegam R ， Coothankandaswamy V ，et al. Loss of Hfe leads to progression of tumor phenotype in primary retinal pigment epithelial cells [J]. Invest Ophthalmol Vis Sci， 2013，54(1)∶63－71. DOI： 10.1167/iovs.12-10312 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Yuan Z ， Feng W ， Hong J ，et al. p38MAPK and ERK promote nitric oxide production in cultured human retinal pigmented epithelial cells induced by high concentration glucose[J]. Nitric Oxide， 2009，20(1)∶9－15. DOI： 10.1016/j.niox.2008.09.001 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Wakisaka M ， Yoshinari M ， Yamamoto M ，et al. Na ＋-dependent glucose uptake and collagen synthesis by cultured bovine retinal pericytes [J]. Biochim Biophys Acta， 1997，1362(1)∶87－96. DOI： 10.1016/s0925-4439(97)00071-9 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Wakisaka M ， Kitazono T ， Kato M ，et al. Sodium-coupled glucose transporter as a functional glucose sensor of retinal microvascular circulation[J]. Circ Res， 2001，88(11)∶1183－1188. DOI： 10.1161/hh1101.091265 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Wakisaka M ， Nagao T ， Yoshinari M ．Sodium glucose cotransporter 2 (SGLT2) plays as a physiological glucose sensor and regulates cellular contractility in rat mesangial cells[J/OL]. PLoS One， 2016，11(3)∶e0151585[2023－12－10]. https://pubmed.ncbi.nlm.nih.gov/26999015/. DOI： 10.1371/journal.pone.0151585 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Wakisaka M ， Yoshinari M ， Asano T ，et al. Normalization of glucose entry under the high glucose condition by phlorizin attenuates the high glucose-induced morphological and functional changes of cultured bovine retinal pericytes[J]. Biochim Biophys Acta， 1999，1453(1)∶83－91. DOI： 10.1016/s0925-4439(98)00087-8 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Smith CD ， Hirayama BA ， Wright EM . Baculovirus-mediated expression of the Na ＋/glucose cotransporter in Sf9 cells [J]. Biochim Biophys Acta， 1992，1104(1)∶151－159. DOI： 10.1016/0005-2736(92)90144-b .
返回引文位置Google Scholar
百度学术
万方数据
[20]
Maki T ， Maeno S ， Maeda Y ，et al. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect：a possible role of SGLT2 in mesangial cells[J/OL]. Sci Rep， 2019，9(1)∶4703[2023－12－11]. https://pubmed.ncbi.nlm.nih.gov/30886225/. DOI： 10.1038/s41598-019-41253-7 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
Wright EM . Renal Na ＋-glucose cotransporters [J]. Am J Physiol Renal Physiol， 2001，280(1)∶F10－18. DOI： 10.1152/ajprenal.2001.280.1.F10 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Roy S ， Bae E ， Amin S ，et al. Extracellular matrix，gap junctions，and retinal vascular homeostasis in diabetic retinopathy[J]. Exp Eye Res， 2015，133∶58－68. DOI： 10.1016/j.exer.2014.08.011 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
Klen J ， Goričar K ， Dolžan V ．Genetic variability in sodium-glucose cotransporter 2 influences glycemic control and risk for diabetic retinopathy in type 2 diabetes patients[J]. J Med Biochem， 2020，39(3)∶276－282. DOI： 10.2478/jomb-2019-0040 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
Hattersley AT ， Thorens B ．Type 2 diabetes，SGLT2 inhibitors，and glucose secretion[J]. N Engl J Med， 2015，373(10)∶974－976. DOI： 10.1056/NEJMcibr1506573 .
返回引文位置Google Scholar
百度学术
万方数据
[25]
Song P ， Onishi A ， Koepsell H ，et al. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus[J]. Expert Opin Ther Targets， 2016，20(9)∶1109－1125. DOI： 10.1517/14728222.2016.1168808 .
返回引文位置Google Scholar
百度学术
万方数据
[26]
Cefalo C ， Cinti F ， Moffa S ，et al. Sotagliflozin，the first dual SGLT inhibitor：current outlook and perspectives[J/OL]. Cardiovasc Diabetol， 2019，18(1)∶20[2023－12－11]. https://pubmed.ncbi.nlm.nih.gov/30819210/. DOI： 10.1186/s12933-019-0828-y .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Rieg T ， Vallon V ．Development of SGLT1 and SGLT2 inhibitors[J]. Diabetologia， 2018，61(10)∶2079－2086. DOI： 10.1007/s00125-018-4654-7 .
返回引文位置Google Scholar
百度学术
万方数据
[28]
Zinman B ， Wanner C ， Lachin JM ，et al. Empagliflozin，cardiovascular outcomes，and mortality in type 2 diabetes[J]. N Engl J Med， 2015，373(22)∶2117－2128. DOI： 10.1056/NEJMoa1504720 .
返回引文位置Google Scholar
百度学术
万方数据
[29]
Pareek A ， Chandurkar N ， Naidu K ．Empagliflozin and progression of kidney disease in type 2 diabetes[J/OL]. N Engl J Med， 2016，375(18)∶1800[2023－12－11]. https://pubmed.ncbi.nlm.nih.gov/27806238/. DOI： 10.1056/NEJMc1611290 .
返回引文位置Google Scholar
百度学术
万方数据
[30]
Wilding J ， Bailey C ， Rigney U ，et al. Dapagliflozin therapy for type 2 diabetes in primary care：changes in HbA1c，weight and blood pressure over 2 years follow-up[J]. Prim Care Diabetes， 2017，11(5)∶437－444. DOI： 10.1016/j.pcd.2017.04.004 .
返回引文位置Google Scholar
百度学术
万方数据
[31]
Neal B ， Perkovic V ， Matthews DR . Canagliflozin and cardiovascular and renal events in type 2 diabetes[J/OL]. N Engl J Med， 2017，377(21)∶2099[2023－12－11]. https://pubmed.ncbi.nlm.nih.gov/29166232/. DOI： 10.1056/NEJMc1712572 .
返回引文位置Google Scholar
百度学术
万方数据
[32]
Wiviott SD ， Raz I ， Bonaca MP ，et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med， 2019，380(4)∶347－357. DOI： 10.1056/NEJMoa1812389 .
返回引文位置Google Scholar
百度学术
万方数据
[33]
Mahaffey KW ， Neal B ， Perkovic V ，et al. Canagliflozin for primary and secondary prevention of cardiovascular events：results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)[J]. Circulation， 2018，137(4)∶323－334. DOI： 10.1161/CIRCULATIONAHA.117.032038 .
返回引文位置Google Scholar
百度学术
万方数据
[34]
Wakisaka M ， Kamouchi M ， Kitazono T ．Lessons from the trials for the desirable effects of sodium glucose co-transporter 2 inhibitors on diabetic cardiovascular events and renal dysfunction[J/OL]. Int J Mol Sci， 2019，20(22)∶5668[2023－12－12]. https://pubmed.ncbi.nlm.nih.gov/31726765/. DOI： 10.3390/ijms20225668 .
返回引文位置Google Scholar
百度学术
万方数据
[35]
Takakura S ， Toyoshi T ， Hayashizaki Y ，et al. Effect of ipragliflozin，an SGLT2 inhibitor，on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats[J]. Life Sci， 2016，147∶125－131. DOI： 10.1016/j.lfs.2016.01.042 .
返回引文位置Google Scholar
百度学术
万方数据
[36]
Chung YR ， Ha KH ， Lee K ，et al. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression：a real-world Korean study[J/OL]. PLoS One， 2019，14(10)∶e0224549[2023－12－10]. https://pubmed.ncbi.nlm.nih.gov/31658289/. DOI： 10.1371/journal.pone.0224549 .
返回引文位置Google Scholar
百度学术
万方数据
[37]
Dziuba J ， Alperin P ， Racketa J ，et al. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes[J]. Diabetes Obes Metab， 2014，16(7)∶628－635. DOI： 10.1111/dom.12261 .
返回引文位置Google Scholar
百度学术
万方数据
[38]
金佩瑶，彭金娟，邹海东，等．上海市新泾社区2型糖尿病居民5年随访的前瞻性调查研究1.糖尿病视网膜病变和糖尿病黄斑水肿的发病率及危险因素[J]. 中华实验眼科杂志， 2016，34(4)∶363－367. DOI： 10.3760/cma.j.issn.2095-0160.2016.04.016 .
返回引文位置Google Scholar
百度学术
万方数据
Jin PY ， Peng JJ ， Zou HD ，et al. A 5-year prospective study of type 2 diabetes patients in Shanghai Xinjing Community 1.The incidence and risk factors of diabetic retinopathy and diabetic macular edema in Chinese type 2 diabetes[J]. Chin J Exp Ophthalmol， 2016，34(4)∶363－367. DOI： 10.3760/cma.j.issn.2095-0160.2016.04.016 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[39]
赵梦雅，许迅．伴脂代谢紊乱的糖尿病视网膜病变研究进展[J]. 中华实验眼科杂志， 2017，35(7)∶655－659. DOI： 10.3760/cma.j.issn.2095-0160.2017.07.017 .
返回引文位置Google Scholar
百度学术
万方数据
Zhao MY ， Xu X ．Research progress of diabetic retinopathy with dyslipidemia[J]. Chin J Exp Ophthalmol， 2017，35(7)∶655－659. DOI： 10.3760/cma.j.issn.2095-0160.2017.07.017 .
Goto CitationGoogle Scholar
Baidu Scholar
Wanfang Data
[40]
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes：UKPDS 38.UK Prospective Diabetes Study Group[J]. BMJ， 1998，317(7160)∶703－713.
返回引文位置Google Scholar
百度学术
万方数据
[41]
Ott C ， Jumar A ， Striepe K ，et al. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation[J/OL]. Cardiovasc Diabetol， 2017，16(1)∶26[2023－12－12]. https://pubmed.ncbi.nlm.nih.gov/28231831/. DOI： 10.1186/s12933-017-0510-1 .
返回引文位置Google Scholar
百度学术
万方数据
[42]
Peene B ， Benhalima K ．Sodium glucose transporter protein 2 inhibitors：focusing on the kidney to treat type 2 diabetes[J]. Ther Adv Endocrinol Metab， 2014，5(5)∶124－136. DOI： 10.1177/2042018814553965 .
返回引文位置Google Scholar
百度学术
万方数据
[43]
Shin SJ ， Chung S ， Kim SJ ，et al. Effect of sodium-glucose co-transporter 2 inhibitor，dapagliflozin，on renal renin-angiotensin system in an animal model of type 2 diabetes[J/OL]. PLoS One， 2016，11(11)∶e0165703[2023－12－12]. https://pubmed.ncbi.nlm.nih.gov/27802313/. DOI： 10.1371/journal.pone.0165703 .
返回引文位置Google Scholar
百度学术
万方数据
[44]
Zhang HY ， Wang JY ， Ying GS ，et al. Serum lipids and other risk factors for diabetic retinopathy in Chinese type 2 diabetic patients[J]. J Zhejiang Univ Sci B， 2013，14(5)∶392－399. DOI： 10.1631/jzus.B1200237 .
返回引文位置Google Scholar
百度学术
万方数据
[45]
Li J ， Wang JJ ， Chen D ，et al. Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes[J]. Exp Eye Res， 2009，89(1)∶71－78. DOI： 10.1016/j.exer.2009.02.013 .
返回引文位置Google Scholar
百度学术
万方数据
[46]
Filippas-Ntekouan S ， Tsimihodimos V ， Filippatos T ，et al. SGLT-2 inhibitors：pharmacokinetics characteristics and effects on lipids[J]. Expert Opin Drug Metab Toxicol， 2018，14(11)∶1113－1121. DOI： 10.1080/17425255.2018.1541348 .
返回引文位置Google Scholar
百度学术
万方数据
[47]
Wakisaka M ．Empagliflozin and progression of kidney disease in type 2 diabetes[J]. N Engl J Med， 2016，375(18)∶1799－1800. DOI： 10.1056/NEJMc1611290 .
返回引文位置Google Scholar
百度学术
万方数据
[48]
Jumar A ， Ott C ， Kistner I ，et al. Early signs of end-organ damage in retinal arterioles in patients with type 2 diabetes compared to hypertensive patients[J]. Microcirculation， 2016，23(6)∶447－455. DOI： 10.1111/micc.12291 .
返回引文位置Google Scholar
百度学术
万方数据
[49]
Green J ， Yurdagul A Jr， McInnis MC ，et al. Flow patterns regulate hyperglycemia-induced subendothelial matrix remodeling during early atherogenesis[J]. Atherosclerosis， 2014，232(2)∶277－284. DOI： 10.1016/j.atherosclerosis.2013.11.052 .
返回引文位置Google Scholar
百度学术
万方数据
[50]
Lacolley P ， Regnault V ， Nicoletti A ，et al. The vascular smooth muscle cell in arterial pathology：a cell that can take on multiple roles[J]. 2012，95(2)∶194－204. DOI： 10.1093/cvr/cvs135 .
返回引文位置Google Scholar
百度学术
万方数据
[51]
Herat LY ， Ward NC ， Magno AL ，et al. Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice[J]. World J Gastroenterol， 2020，26(23)∶3225－3235. DOI： 10.3748/wjg.v26.i23.3225 .
返回引文位置Google Scholar
百度学术
万方数据
[52]
Sapieha P ， Sirinyan M ， Hamel D ，et al. The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis[J]. Nat Med， 2008，14(10)∶1067－1076. DOI： 10.1038/nm.1873 .
返回引文位置Google Scholar
百度学术
万方数据
[53]
Matthews VB ， Elliot RH ， Rudnicka C ，et al. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2[J]. J Hypertens， 2017，35(10)∶2059－2068. DOI： 10.1097/HJH.0000000000001434 .
返回引文位置Google Scholar
百度学术
万方数据
[54]
Kramer CK ， Leitão CB ， Azevedo MJ ，et al. Diabetic retinopathy is associated with early autonomic dysfunction assessed by exercise-related heart rate changes[J]. Braz J Med Biol Res， 2008，41(12)∶1110－1115. DOI： 10.1590/s0100-879x2008001200011 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
邹海东，Email： nc.defudabe.utjsgnodiahuoz
B
所有作者均声明不存在利益冲突
C
上海市眼科疾病精准诊疗工程技术研究中心项目 (19DZ2250100)
上海市加强公共卫生体系建设三年行动计划重点学科项目 (GWVI-11.1-30)
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
西黄丸治疗胃癌作用机制的网络药理学和机器学习探讨
王励之 等
国际医药卫生导报 2024,30(23)
基于网络药理学和分子对接技术探究苓桂术甘汤干预高血压病和肥胖症“异病同治”作用机制
李纪新 等
国际中医中药杂志 2023,45(04)
基于网络药理学探讨天水涤肠汤治疗溃疡性结肠炎作用机制及实验验证
李培通 等
国际中医中药杂志 2023,45(11)
基于网络药理学的中药蒲公英治疗乳腺癌作用机制研究
刘婷婷 等
国际中医中药杂志 2021,43(09)
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大